Trial Profile

Phase I study assessing SCI-160 for treatment of pain

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 04 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SCI-160 (Primary)
Indications Pain
Focus Adverse reactions
Sponsors SciSparc

Most Recent Events

04 Apr 2022 New trial record
30 Mar 2022 According to SciSparc media release, the company intends to submit FDA Investigational New Drug (IND) Phase I study application for treatment for pain in 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com